Trial Outcomes & Findings for Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents (NCT NCT01102374)

NCT ID: NCT01102374

Last Updated: 2017-04-21

Results Overview

ARIs defined as upper or lower respiratory infections

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

107 participants

Primary outcome timeframe

12 months

Results posted on

2017-04-21

Participant Flow

Participant milestones

Participant milestones
Measure
High Dose Vitamin D
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Overall Study
STARTED
55
52
Overall Study
COMPLETED
39
33
Overall Study
NOT COMPLETED
16
19

Reasons for withdrawal

Reasons for withdrawal
Measure
High Dose Vitamin D
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Overall Study
Death
9
13
Overall Study
Lost to Follow-up
7
6

Baseline Characteristics

Vitamin D Supplementation and Acute Respiratory Infection in Older Long-Term Care Residents

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
High Dose Vitamin D
n=55 Participants
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 Participants
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Total
n=107 Participants
Total of all reporting groups
Age, Continuous
80 years
STANDARD_DEVIATION 10 • n=5 Participants
82 years
STANDARD_DEVIATION 10 • n=7 Participants
81 years
STANDARD_DEVIATION 10 • n=5 Participants
Sex: Female, Male
Female
33 Participants
n=5 Participants
29 Participants
n=7 Participants
62 Participants
n=5 Participants
Sex: Female, Male
Male
22 Participants
n=5 Participants
23 Participants
n=7 Participants
45 Participants
n=5 Participants
Region of Enrollment
United States
55 participants
n=5 Participants
52 participants
n=7 Participants
107 participants
n=5 Participants
25-hydroxyvitamin D level
23.0 ng/ml
STANDARD_DEVIATION 8.4 • n=5 Participants
23.0 ng/ml
STANDARD_DEVIATION 9.9 • n=7 Participants
23.0 ng/ml
STANDARD_DEVIATION 9.1 • n=5 Participants

PRIMARY outcome

Timeframe: 12 months

ARIs defined as upper or lower respiratory infections

Outcome measures

Outcome measures
Measure
High Dose Vitamin D
n=55 Participants
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 Participants
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Number of Acute Respiratory Infections (ARIs)
32 events
48 events

SECONDARY outcome

Timeframe: 12 month

ARIs resulting in emergency department visits or hospitalizations

Outcome measures

Outcome measures
Measure
High Dose Vitamin D
n=55 Participants
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 Participants
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Severity of Acute Respiratory Infections
3 events
6 events

SECONDARY outcome

Timeframe: 12 months

Outcome measures

Outcome measures
Measure
High Dose Vitamin D
n=55 Participants
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 Participants
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Time to First ARI
0.59 Hazard Ratio
1.00 Hazard Ratio

SECONDARY outcome

Timeframe: Baseline and 12 months

Outcome measures

Outcome measures
Measure
High Dose Vitamin D
n=55 Participants
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 Participants
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Change in 25-hydroxyvitamin D (25OHD) Level
8.18 ng/mL
Standard Error 0.75
2.71 ng/mL
Standard Error 0.80

SECONDARY outcome

Timeframe: Baseline and 12 months

Population: Issue relating to sample collection/processing precluded measurement of PTH level in the trial

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 12 months

Outcome measures

Outcome measures
Measure
High Dose Vitamin D
n=55 Participants
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 Participants
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Falls
70 Events
27 Events

SECONDARY outcome

Timeframe: 12 months

Outcome measures

Outcome measures
Measure
High Dose Vitamin D
n=55 Participants
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 Participants
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Fractures
5 events
8 events

SECONDARY outcome

Timeframe: 12 months

Outcome measures

Outcome measures
Measure
High Dose Vitamin D
n=55 Participants
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 Participants
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Number of Upper Respiratory Infections
21 events
36 events

SECONDARY outcome

Timeframe: 12 months

Outcome measures

Outcome measures
Measure
High Dose Vitamin D
n=55 Participants
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 Participants
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Number of Lower Respiratory Infections
11 events
12 events

SECONDARY outcome

Timeframe: 12 months

Population: collected together with lower respiratory infections (not as a separate category)

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 12 months

Outcome measures

Outcome measures
Measure
High Dose Vitamin D
n=55 Participants
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 Participants
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Incident Kidney Stones
0 Participants
0 Participants

SECONDARY outcome

Timeframe: 12 months

Outcome measures

Outcome measures
Measure
High Dose Vitamin D
n=55 Participants
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 Participants
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Incident Hypercalcemia
0 Participants
0 Participants

SECONDARY outcome

Timeframe: 12 months

Outcome measures

Outcome measures
Measure
High Dose Vitamin D
n=55 Participants
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 Participants
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Death
9 Participants
13 Participants

SECONDARY outcome

Timeframe: 12 months

Outcome measures

Outcome measures
Measure
High Dose Vitamin D
n=55 Participants
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 Participants
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Number of Urinary Tract Infections
38 events
22 events

SECONDARY outcome

Timeframe: 12 months

Outcome measures

Outcome measures
Measure
High Dose Vitamin D
n=55 Participants
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 Participants
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Number of Other Infections
33 events
43 events

Adverse Events

High Dose Vitamin D

Serious events: 9 serious events
Other events: 53 other events
Deaths: 0 deaths

Standard Dose Vitamin D

Serious events: 13 serious events
Other events: 49 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
High Dose Vitamin D
n=55 participants at risk
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 participants at risk
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
General disorders
Death
16.4%
9/55 • Number of events 9
25.0%
13/52 • Number of events 13

Other adverse events

Other adverse events
Measure
High Dose Vitamin D
n=55 participants at risk
100,000 IU Vitamin D3 (cholecalciferol) monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 3,300-4,300 IU per day. High Dose Vitamin D: Vitamin D3 100,000 IU monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Standard Dose Vitamin D
n=52 participants at risk
12,000 IU Vitamin D3 (cholecalciferol) or placebo monthly for 12 months. When added to usual care (0-1000 IU Vitamin D per day), averages 400-1,000 IU per day. Standard Dose Vitamin D: Vitamin D 12,000 IU monthly Placebo: Placebo monthly Usual Care: Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
Blood and lymphatic system disorders
Blood and lymphatic system disorders
12.7%
7/55
7.7%
4/52
Cardiac disorders
Cardiac disorders
27.3%
15/55
17.3%
9/52
Ear and labyrinth disorders
Ear and labyrinth disorders
10.9%
6/55
1.9%
1/52
Endocrine disorders
Endocrine disorders
5.5%
3/55
0.00%
0/52
Eye disorders
Eye disorders
9.1%
5/55
13.5%
7/52
Gastrointestinal disorders
Gastrointestinal disorders
40.0%
22/55
51.9%
27/52
General disorders
General disorders
70.9%
39/55
53.8%
28/52
Hepatobiliary disorders
Hepatobiliary disorders
1.8%
1/55
1.9%
1/52
Immune system disorders
Immune system disorders
16.4%
9/55
13.5%
7/52
Infections and infestations
Infections and infestations
38.2%
21/55
40.4%
21/52
Injury, poisoning and procedural complications
Injury, poisoning, and procedural complications
52.7%
29/55
57.7%
30/52
Investigations
Investigations
29.1%
16/55
23.1%
12/52
Metabolism and nutrition disorders
Metabolic and nutrition disorders
32.7%
18/55
28.8%
15/52
Musculoskeletal and connective tissue disorders
Musculoskeletal and connective tissue disorders
30.9%
17/55
30.8%
16/52
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasms
1.8%
1/55
1.9%
1/52
Nervous system disorders
Nervous system disorders
18.2%
10/55
19.2%
10/52
Psychiatric disorders
Psychiatric disorders
54.5%
30/55
36.5%
19/52
Renal and urinary disorders
Renal and urinary disorders
23.6%
13/55
19.2%
10/52
Reproductive system and breast disorders
Reproductive system disorders
10.9%
6/55
3.8%
2/52
Respiratory, thoracic and mediastinal disorders
Respiratory, thoracic, and mediastinal disorders
43.6%
24/55
57.7%
30/52
Skin and subcutaneous tissue disorders
Skin and subcutaneous disorders
41.8%
23/55
42.3%
22/52
Social circumstances
Social circumstances
1.8%
1/55
0.00%
0/52
Surgical and medical procedures
Surgical and medical procedures
25.5%
14/55
11.5%
6/52

Additional Information

Adit Ginde, MD, MPH, Professor of Emergency Medicine

University of Colorado School of Medicine

Phone: 720-848-6777

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place